Cholinhydrogentartrat API Manufacturers
compare suppliers & get competitive offers
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Cholinhydrogentartrat API 87-67-2?
- Here you will find a list of producers, manufacturers and traders of Cholinhydrogentartrat. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Cas Number:
- DrugBank number:
- Unique Ingredient Identifier:
Cholinhydrogentartrat is a type of Parasympathomimetics
Parasympathomimetics are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that mimic the effects of the parasympathetic nervous system. The parasympathetic nervous system is responsible for regulating various bodily functions, such as digestion, salivation, and urinary bladder control.
Parasympathomimetic drugs work by activating the receptors in the parasympathetic nervous system, leading to increased activity in the targeted organ or system. These drugs are commonly used to treat conditions related to decreased parasympathetic activity, such as dry mouth, urinary retention, and gastrointestinal disorders.
One example of a parasympathomimetic drug is pilocarpine, which is used to treat conditions like dry mouth caused by Sjogren's syndrome or radiation therapy. Pilocarpine stimulates the salivary glands, increasing saliva production and relieving dryness.
Another widely used parasympathomimetic drug is Bethanechol, which is used to treat urinary retention. By stimulating the detrusor muscle of the bladder, Bethanechol promotes bladder emptying.
Parasympathomimetics can have side effects such as excessive salivation, sweating, and gastrointestinal disturbances. Therefore, their use should be carefully monitored and prescribed by healthcare professionals.
In conclusion, parasympathomimetics are a valuable subcategory of pharmaceutical APIs that play a crucial role in regulating parasympathetic nervous system activity. These drugs offer therapeutic benefits for various medical conditions and should be used under proper medical guidance to ensure optimal outcomes for patients.
Cholinhydrogentartrat (Parasympathomimetics), classified under Autonomic Nervous System Agents
Autonomic Nervous System Agents are a crucial category of pharmaceutical active ingredients (APIs) that target the autonomic nervous system (ANS). The ANS plays a vital role in regulating essential bodily functions such as heart rate, blood pressure, digestion, and respiratory rate. This category of pharmaceutical APIs encompasses a wide range of drugs designed to modulate the activity of the ANS.
One subcategory within Autonomic Nervous System Agents is the Sympathomimetic agents, which mimic the effects of the sympathetic nervous system. These drugs are often used to treat conditions such as asthma, nasal congestion, and hypotension by stimulating specific adrenergic receptors.
Conversely, Sympatholytic agents act to inhibit or block the sympathetic nervous system. They are employed to treat hypertension, anxiety, and certain cardiac conditions by reducing sympathetic activity.
Another subcategory is Parasympathomimetic agents, which mimic the effects of the parasympathetic nervous system. These drugs are commonly used to treat glaucoma, urinary retention, and certain gastrointestinal disorders by stimulating cholinergic receptors.
Parasympatholytic agents, on the other hand, act to block the parasympathetic nervous system. They find applications in the treatment of conditions such as overactive bladder and irritable bowel syndrome by inhibiting cholinergic receptors.
The Autonomic Nervous System Agents API category includes various drugs with distinct mechanisms of action that enable healthcare professionals to fine-tune the balance of the autonomic nervous system. By targeting specific receptors and pathways, these pharmaceutical APIs provide valuable therapeutic options for managing a wide range of medical conditions related to autonomic dysfunction.